Research & Development Expenses
The latest quarterly r&d expense is $89.70 Million with a quarter-over-quarter change of -1.32%. Research and Development (R&D) expenses represent the costs incurred by a company in developing new products, services, or processes.
PODD R&D Expense
Reported quarterly R&D expense; no daily interpolation.
Current R&D Expense
$89.70M
$89.70 Million
Quarter-over-Quarter Change
-1.32%
vs. $90.90M prior quarter
Historical Data
85
Quarters of data available
Quarterly R&D Expense History
| Period | R&D Expense | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $89.70M | $-1.20M | -1.32% |
| Q4 2025 | $90.90M | +$13.70M | +17.75% |
| Q3 2025 | $77.20M | +$3.80M | +5.18% |
| Q2 2025 | $73.40M | +$13.80M | +23.15% |
| Q1 2025 | $59.60M | $-1.00M | -1.65% |
| Q4 2024 | $60.60M | +$5.70M | +10.38% |
| Q3 2024 | $54.90M | +$1.00M | +1.86% |
| Q2 2024 | $53.90M | +$3.70M | +7.37% |
| Q1 2024 | $50.20M | +$8.20M | +19.52% |
| Q4 2023 | $42.00M | $-15.80M | -27.34% |
| Q3 2023 | $57.80M | +$2.70M | +4.90% |
| Q2 2023 | $55.10M | +$5.00M | +9.98% |
| Q1 2023 | $50.10M | +$600,000 | +1.21% |
| Q4 2022 | $49.50M | +$4.50M | +10.00% |
| Q3 2022 | $45.00M | +$2.40M | +5.63% |
| Q2 2022 | $42.60M | $-500,000 | -1.16% |
| Q1 2022 | $43.10M | +$1.30M | +3.11% |
| Q4 2021 | $41.80M | +$4.30M | +11.47% |
| Q3 2021 | $37.50M | $-2.60M | -6.48% |
| Q2 2021 | $40.10M | $-600,000 | -1.47% |
| Q1 2021 | $40.70M | +$2.40M | +6.27% |
| Q4 2020 | $38.30M | $-500,000 | -1.29% |
| Q3 2020 | $38.80M | +$4.60M | +13.45% |
| Q2 2020 | $34.20M | $-1.30M | -3.66% |
| Q1 2020 | $35.50M | +$800,000 | +2.31% |
| Q4 2019 | $34.70M | +$3.92M | +12.74% |
| Q3 2019 | $30.78M | $-1.49M | -4.60% |
| Q2 2019 | $32.26M | +$310,000 | +0.97% |
| Q1 2019 | $31.95M | +$3.44M | +12.06% |
| Q4 2018 | $28.51M | +$6.75M | +31.03% |
| Q3 2018 | $21.76M | +$3.34M | +18.16% |
| Q2 2018 | $18.42M | $-1.49M | -7.50% |
| Q1 2018 | $19.91M | +$1.13M | +6.02% |
| Q4 2017 | $18.78M | $-1.36M | -6.75% |
| Q3 2017 | $20.14M | +$2.11M | +11.71% |
| Q2 2017 | $18.03M | +$529,000 | +3.02% |
| Q1 2017 | $17.50M | +$1.47M | +9.14% |
| Q4 2016 | $16.03M | +$2.30M | +16.75% |
| Q3 2016 | $13.73M | +$781,000 | +6.03% |
| Q2 2016 | $12.95M | $-36,000 | -0.28% |
| Q1 2016 | $12.99M | +$92,000 | +0.71% |
| Q4 2015 | $12.90M | +$2.86M | +28.52% |
| Q3 2015 | $10.04M | $-2.03M | -16.85% |
| Q2 2015 | $12.07M | +$3.86M | +47.06% |
| Q1 2015 | $8.21M | +$921,000 | +12.64% |
| Q4 2014 | $7.29M | +$128,000 | +1.79% |
| Q3 2014 | $7.16M | +$481,000 | +7.20% |
| Q2 2014 | $6.68M | $-102,000 | -1.50% |
| Q1 2014 | $6.78M | +$355,000 | +5.53% |
| Q4 2013 | $6.42M | +$653,000 | +11.32% |
| Q3 2013 | $5.77M | +$597,000 | +11.54% |
| Q2 2013 | $5.17M | +$778,000 | +17.70% |
| Q1 2013 | $4.40M | $-1.45M | -24.82% |
| Q4 2012 | $5.85M | $-712,000 | -10.86% |
| Q3 2012 | $6.56M | +$38,000 | +0.58% |
| Q2 2012 | $6.52M | +$1.09M | +20.05% |
| Q1 2012 | $5.43M | $-372,000 | -6.41% |
| Q4 2011 | $5.80M | +$1.17M | +25.14% |
| Q3 2011 | $4.64M | $-2.19M | -32.11% |
| Q2 2011 | $6.83M | +$2.24M | +48.88% |
| Q1 2011 | $4.59M | +$151,000 | +3.40% |
| Q4 2010 | $4.44M | +$740,000 | +20.01% |
| Q3 2010 | $3.70M | $-885,000 | -19.31% |
| Q2 2010 | $4.58M | +$736,000 | +19.13% |
| Q1 2010 | $3.85M | +$496,000 | +14.80% |
| Q4 2009 | $3.35M | $-53,000 | -1.56% |
| Q3 2009 | $3.40M | +$132,000 | +4.03% |
| Q2 2009 | $3.27M | +$68,000 | +2.12% |
| Q1 2009 | $3.20M | $-331,000 | -9.36% |
| Q4 2008 | $3.54M | +$272,000 | +8.34% |
| Q3 2008 | $3.26M | $-119,000 | -3.52% |
| Q2 2008 | $3.38M | +$459,000 | +15.70% |
| Q1 2008 | $2.92M | $-247,000 | -7.79% |
| Q4 2007 | $3.17M | +$939,000 | +42.09% |
| Q3 2007 | $2.23M | $-289,000 | -11.47% |
| Q2 2007 | $2.52M | +$50,000 | +2.02% |
| Q1 2007 | $2.47M | +$267,000 | +12.12% |
| Q4 2006 | $2.20M | +$239,000 | +12.17% |
| Q3 2006 | $1.96M | +$1.96M | — |
| Q2 2006 | $0 | +$0 | — |
| Q1 2006 | $0 | +$0 | — |
| Q4 2005 | $0 | +$0 | — |
| Q3 2005 | $0 | +$0 | — |
| Q2 2005 | $0 | +$0 | — |
| Q1 2005 | $0 | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy